AMGN vs PFE
Amgen and Pfizer, both Healthcare
Amgen is the larger company at $182B against $144B. On trailing earnings AMGN is the cheaper of the two at a P/E of 27.4 against 37.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +59% against +24% for PFE. Ryufin's sector-relative Smart Score puts AMGN ahead, 9/10 against 7/10.
| Figure | AMGN | PFE |
|---|---|---|
| Last close | $440 | $28.32 |
| Market cap | $182B | $144B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.4 | 37.3 |
| Dividend yield | 2.2% | 6.1% |
| 1-year return | +59% | +24% |
| 5-year return | +113% | -15% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 15% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.